Previous 10 | Next 10 |
Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity ...
IsoPlexis Corporation (ISO) Q3 2022 Earnings Conference Call November 10, 2022, 17:30 pm ET Company Participants Carrie Mendivil - IR Sean Mackay - CEO John Strahley - CFO Conference Call Participants Jordan Adler - Evercore ISI Joe Giordano - Cow...
IsoPlexis press release ( NASDAQ: ISO ): Q3 GAAP EPS of -$0.47. Revenue of $4.5M (+7.1% Y/Y). Q3 2022 gross margin was 50%. Sold 23 new instruments in the Q3, bringing cumulative instruments sold to 277. Expects full year 2022 revenue to increase by 11%-15% ove...
BRANFORD, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today reported financial results for the quarter ended September 30, 2022. Recent Highlights ...
BRANFORD, Conn., Nov. 09, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will be participating in the following investor conferences. Canaccord Genuity...
BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will report financial results for the third quarter 2022 before market open on Thursda...
BRANFORD, Conn., Sept. 13, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO) (“IsoPlexis”), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced the publication of initial data off its CodePlex platform in...
BRANFORD, Conn., Sept. 06, 2022 (GLOBE NEWSWIRE) -- IsoPlexis (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a partnership with MediMergent, LLC, and The Center for Cancer and Blood Disorders (CCBD), ...
BRANFORD, Conn., Aug. 31, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO) (“IsoPlexis”), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will be participating in the upcoming Morgan Stanley Globa...
BRANFORD, Conn., Aug. 23, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO) (“IsoPlexis”), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced the appointment of Nachum “Homi” Shamir to its ...
News, Short Squeeze, Breakout and More Instantly...
(NewsDirect) IsoEnergy Limited (TSX-V:ISO) president Tim Gabruch, delves into the strategic merger with Consolidated Uranium, marking a pivotal transformation into a global uranium industry contender. In an interview with Proactive's Angela Harmantas at PDAC 2024, Gabruch noted that t...
SASKATOON, Saskatchewan, Jan. 19, 2024 (GLOBE NEWSWIRE) -- IsoEnergy Ltd. (“IsoEnergy” or the “Company”) (TSXV: ISO; OTCQX: ISENF) is pleased to announce that it has entered into an amended agreement with Eight Capital, as co-lead underwriter and joint bookrunner o...
SASKATOON, Saskatchewan, Jan. 18, 2024 (GLOBE NEWSWIRE) -- IsoEnergy Ltd. (“IsoEnergy” or the “Company”) (TSXV: ISO; OTCQX: ISENF) is pleased to announce that it has entered into an agreement with Eight Capital to act as co-lead underwriter and joint bookrunner on ...